Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-021-01616-9
Abstract: Phosphodiesterase (PDE) 4 inhibitors prevent the metabolism of cyclic adenosine monophosphate, thereby reducing inflammation. Inhaled PDE4 inhibitors aim to restrict systemic drug exposure to enhance the potential for clinical benefits (in the lungs) versus adverse… read more here.
Keywords: chronic obstructive; obstructive pulmonary; phosphodiesterase inhibitors; pulmonary disease ... See more keywords
Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2020.00259
Abstract: PDE4 inhibitors can suppress a variety of inflammatory cell functions that contribute to their anti-inflammatory actions in respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma. The systemically delivered PDE4 inhibitor roflumilast has been… read more here.
Keywords: phosphodiesterase pde4; pde4 inhibitors; respiratory diseases; pde4 ... See more keywords